No Data
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Maintains Target Price $18
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $33 to $51
No Data
No Data